Literature DB >> 31863960

Cell cycle progression is disrupted in murine MPS VII growth plate leading to reduced chondrocyte proliferation and transition to hypertrophy.

Zhirui Jiang1, Ainslie L K Derrick-Roberts2, Clare Reichstein2, Sharon Byers3.   

Abstract

Endochondral bone growth is abnormal in 6 of the 11 types of mucopolysaccharidoses (MPS) disorders; resulting in short stature, reduced size of the thoracic cavity and compromised manual dexterity. Current therapies for MPS have had a limited effect on bone growth and to improve these therapies or develop adjunct approaches requires an understanding of the underlying basis of abnormal bone growth in MPS. The MPS VII mouse model replicates the reduction in long bone and vertebral length observed in human MPS. Using this model we have shown that the growth plate is elongated but contains fewer chondrocytes in the proliferative and hypertrophic zones. Endochondral bone growth is in part regulated by entry and exit from the cell cycle by growth plate chondrocytes. More MPS VII chondrocytes were positive for Ki67, a marker for active phases of the cell cycle, suggesting that more MPS VII chondrocytes were in the cell cycle. The number of cells positive for phosphorylated histone H3 was significantly reduced in MPS VII chondrocytes, suggesting fewer MPS VII chondrocytes progressed to mitotic division. While MPS VII HZ chondrocytes continued to express cyclin D1 and more cells were positive for E2F1 and phos pRb than normal, fewer MPS VII HZ chondrocytes were positive for p57kip2 a marker of terminal differentiation, suggesting fewer MPS VII chondrocytes were able to exit the cell cycle. In addition, multiple markers typical of PZ to HZ transition were not downregulated in MPS VII, in particular Sox9, Pthrpr and Wnt5a. These findings are consistent with MPS VII growth plates elongating at a slower rate than normal due to a delay in progression through the cell cycle, in particular the transition between G1 and S phases, leading to both reduced cell division and transition to the hypertrophic phenotype.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cell cycle; Chondrocyte proliferation; Endochondral ossification; Hypertrophic differentiation; Lysosomal storage disorder; Mucopolysaccharidosis

Mesh:

Year:  2019        PMID: 31863960     DOI: 10.1016/j.bone.2019.115195

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  6 in total

Review 1.  Failures of Endochondral Ossification in the Mucopolysaccharidoses.

Authors:  Zhirui Jiang; Sharon Byers; Margret L Casal; Lachlan J Smith
Journal:  Curr Osteoporos Rep       Date:  2020-10-16       Impact factor: 5.096

2.  Epiphyseal cartilage canal architecture and extracellular matrix remodeling in mucopolysaccharidosis VII dogs at the onset of postnatal growth.

Authors:  Zhirui Jiang; Casey P Johnson; Olli Nykänen; Mikko Nissi; Yian Khai Lau; Meilun Wu; Margret L Casal; Lachlan J Smith
Journal:  Connect Tissue Res       Date:  2021-01-11       Impact factor: 3.417

Review 3.  Bone Biomarkers in Mucopolysaccharidoses.

Authors:  Akari Nakamura-Utsunomiya
Journal:  Int J Mol Sci       Date:  2021-11-23       Impact factor: 5.923

4.  Fluorine impairs carboxylesterase 1-mediated hydrolysis of T-2 toxin and increases its chondrocyte toxicity.

Authors:  Yumeng Jia; Sirong Shi; Bolun Cheng; Shiqiang Cheng; Li Liu; Peilin Meng; Xuena Yang; Xiaoge Chu; Yan Wen; Feng Zhang; Xiong Guo
Journal:  Front Nutr       Date:  2022-08-03

Review 5.  MPSI Manifestations and Treatment Outcome: Skeletal Focus.

Authors:  Giada De Ponti; Samantha Donsante; Marta Frigeni; Alice Pievani; Alessandro Corsi; Maria Ester Bernardo; Mara Riminucci; Marta Serafini
Journal:  Int J Mol Sci       Date:  2022-09-22       Impact factor: 6.208

6.  Progression of vertebral bone disease in mucopolysaccharidosis VII dogs from birth to skeletal maturity.

Authors:  Sun H Peck; Yian Khai Lau; Jennifer L Kang; Megan Lin; Toren Arginteanu; Dena R Matalon; Justin R Bendigo; Patricia O'Donnell; Mark E Haskins; Margret L Casal; Lachlan J Smith
Journal:  Mol Genet Metab       Date:  2021-06-15       Impact factor: 4.204

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.